FY2025 EPS Forecast for Olema Pharmaceuticals Cut by Analyst

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at Lifesci Capital decreased their FY2025 earnings per share (EPS) estimates for Olema Pharmaceuticals in a research report issued on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($2.28) for the year, down from their prior forecast of ($2.12). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share.

A number of other analysts have also issued reports on the company. Oppenheimer reissued an “outperform” rating and issued a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday.

Olema Pharmaceuticals Stock Up 2.7 %

OLMA opened at $4.23 on Friday. The business’s fifty day simple moving average is $5.09 and its 200 day simple moving average is $8.33. Olema Pharmaceuticals has a 52 week low of $3.94 and a 52 week high of $16.62. The firm has a market cap of $242.37 million, a P/E ratio of -1.93 and a beta of 2.11.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12.

Hedge Funds Weigh In On Olema Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of Olema Pharmaceuticals by 658.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock valued at $2,162,000 after purchasing an additional 157,171 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Olema Pharmaceuticals by 9.9% during the 3rd quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock valued at $10,167,000 after buying an additional 76,720 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Olema Pharmaceuticals by 80.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company’s stock valued at $1,237,000 after buying an additional 94,651 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Olema Pharmaceuticals by 168.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after buying an additional 207,565 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Olema Pharmaceuticals by 10.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after buying an additional 97,428 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, January 8th. The shares were acquired at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the purchase, the insider now directly owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 19.40% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.